RNA

TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas

Retrieved on: 
Friday, April 14, 2023
Agreement, Glioblastoma, Therapy, Cancer, SEC filing, RNA, Sale, Prospectus, Form, Security (finance)

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”) an investor in the glioblastomas / oncology sector.

Key Points: 
  • BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”) an investor in the glioblastomas / oncology sector.
  • The Agreement provides the Company with the right to sell White Lion Capital up to approximately $1.08 million of its common stock until May 31, 2023, subject to certain limitations and conditions.
  • The Company intends to use the net proceeds from the transaction for working capital and general corporate purposes.
  • The shares of common stock described above will be offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No.

Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics

Retrieved on: 
Friday, April 14, 2023
Health, Medical Devices, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Infection, LSE, DNA, Partnership, CS, Multimedia, RNA, Nanopore sequencing, Oxford Nanopore Technologies, Dicarboxylic acid, Tuberculosis, Nanopore, IVD, ONT, Pharmaceutical industry, Vaccine

Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments.

Key Points: 
  • Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments.
  • It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore.
  • Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer, commented: “We are pleased to partner with bioMérieux’s IVD expertise to add powerful new tools for the fight against infectious disease.
  • New technologies such as sequencing hold promise to improve diagnostics and patient care; our teams will collaborate in this direction.”

MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting

Retrieved on: 
Friday, April 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RNAa, Myelocyte, Interim, AACR, Therapy, Mina, Neoplasm, MTL, Cancer, RNA, EDT, Liver cancer, Patient, Sorafenib, American Association for Cancer Research, Pembrolizumab, Tumor microenvironment, HCC, Safety, Pharmaceutical industry, Vaccine

Findings from the Phase 1b portion of the study validate the clinical proof of mechanism of MTL-CEBPA as a combination treatment and identify a novel predictive biomarker of clinical response.

Key Points: 
  • Findings from the Phase 1b portion of the study validate the clinical proof of mechanism of MTL-CEBPA as a combination treatment and identify a novel predictive biomarker of clinical response.
  • The data will be presented on Tuesday, April 18, during a late-breaking research session beginning at 9:00 am EDT.
  • MTL‑CEBPA is the first therapy that specifically up-regulates CCAAT/enhancer binding protein alpha (C/EBP-α), a transcription factor that acts as a master regulator of myeloid cells.
  • Interim data from an open-label, multi-center study demonstrated the safety, tolerability, immunological and clinical activity of MTL-CEBPA in combination with pembrolizumab.

Agilent Showcases Comprehensive Cancer Portfolio Solutions at AACR 2023

Retrieved on: 
Friday, April 14, 2023
Biotechnology, Genetics, Health, Oncology, DNA, Partnership, AACR, Therapy, CGP, NGS, Cancer, SMAD, Woman, Research, Genomics, RNA, Incidence, Assay, Algorithm, Cell, Cell Signaling Technology, Diagnosis, CDX, Death, NYSE, Medical imaging, Agilent Technologies

Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.

Key Points: 
  • Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.
  • An estimated 41 out of 100 men and 39 out of 100 women will potentially develop cancer during their lifetime1.
  • “Cancer remains a significant area of strategic focus for Agilent.
  • AACR poster sessions will include multiple Agilent research posters and more than 50 additional customer posters featuring Agilent instruments and solutions.

Geneius Biotechnology Announces Poster Presentation at the 2023 AACR Annual Meeting

Retrieved on: 
Friday, April 14, 2023
Poster, AACR, Cell, RNA, HLA, Vaccine

 NATICK, Mass., April 14, 2023 /PRNewswire/ -- Geneius Biotechnology, Inc., an immuno-oncology company developing a best-in-class personalized RNA-enabled T cell therapy platform that generates a robust immune response to solid  and liquid cancers, today announced the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • NATICK, Mass., April 14, 2023 /PRNewswire/ -- Geneius Biotechnology, Inc., an immuno-oncology company developing a best-in-class personalized RNA-enabled T cell therapy platform that generates a robust immune response to solid  and liquid cancers, today announced the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
  • The abstract will be available on the AACR meeting website.
  • The poster will be available online at www.geneiusbiotech.com following the presentation.
  • Abstract 4067 – RNA primed SMAR-T™ cells against multiple driver mutations, all HLA's, designed for first line therapy

M2GEN Rebrands to Aster Insights

Retrieved on: 
Friday, April 14, 2023
DNA, Cancer, Research, Genomics, RNA, TCC, Patient, Sequence, Data, Medicine, Drug discovery, Knowledge, Growth, Industrial design, Pharmaceutical industry, Medical imaging

TAMPA, Fla., April 14, 2023 /PRNewswire/ -- M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomic data to accelerate medical product discovery, today announced it is rebranding, changing the company's name to Aster Insights™.

Key Points: 
  • M2GEN rebrands to Aster Insights, leading oncology bioinformatics company unveils new name, logo, and website.
  • Most importantly, Aster Insights' patient-centric structure is based on lifetime patient consent using the Total Cancer Care® (TCC) protocol, making this the first such longitudinal database of patients with cancer.
  • "The precision medicine and drug discovery markets continue to experience rapid growth, which provides a unique opportunity for Aster Insights to become synonymous with how cancer is studied and treated," said Sandi Peterson, Chairman of the Board, Aster Insights .
  • The company has launched a new website: https://www.AsterInsights.com , which serves as the central information hub for Aster Insights, the company's products and services, ORIEN, and TCC.

Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development

Retrieved on: 
Thursday, April 13, 2023
Chromosome, DNA, CE, Partnership, AACR, TMB, Hematology, HRD, CAP, NGS, Clinical trial, Liquid biopsy, Cancer, Licensure, RNA, Immunophenotyping, GTC, CLIA, MD, Patient, Blood, HPV, Artificial intelligence, Liquid, NYS, EBV, Sysmex Corporation, Vaccine, Pharmaceutical industry

The partnership synergizes GTC's proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next generation sequencing (NGS) profiling, with Sysmex Inostics's global commercial capabilities in biopharma therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.

Key Points: 
  • The partnership synergizes GTC's proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next generation sequencing (NGS) profiling, with Sysmex Inostics's global commercial capabilities in biopharma therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.
  • Shinichi Sato, president, and Chief Executive Officer of Sysmex Inostics, stated, "Our new relationship with GTC extends our commitment to our biopharma partners.
  • We understand not one testing solution fits all stages of therapeutic development and it was imperative to offer our biopharma partners GTC's broader panels for their discovery work."
  • "The alliance with Sysmex Inostics is fundamental to our mission of democratizing genomic testing and making it available and affordable to every patient dealing with cancer.

BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE

Retrieved on: 
Thursday, April 13, 2023
AACR, Cancer, American Association for Cancer Research, RNA, Research, Biomarker, Bio-Techne, BCG, Protein, Patient, Messenger, Pharmaceutical industry

MINNEAPOLIS, April 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida.

Key Points: 
  • MINNEAPOLIS, April 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida.
  • Additionally, several scientists from the Company will present posters with updates on biomarkers of therapeutic benefit, structural and chemical biology, and spatial biology.
  • "I am excited to highlight our broad portfolio of tools, reagents and workflow solutions that enable cancer research at this important conference," commented Chuck Kummeth, President and CEO of Bio-Techne.
  • I am proud of the impact our Company has on research and ultimately improving the lives of patients around the globe."

BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies

Retrieved on: 
Tuesday, April 4, 2023
TRON, Neoplasm, Antigen, DDR, Cancer, Biomedical Research, Research, RNA, Messenger, DNA, Patient, BioMed Central, ISCB Senior Scientist Award, Merck, RNA splicing, Vaccine

After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.

Key Points: 
  • After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
  • HEIDLEBERG, Germany, Apr 4, 2023 - (ACN Newswire) - BioMed X, an independent biomedical research institute, announces the start of its new research project - "New Strategies to Enhance the Immunogenicity of Tumors" - in collaboration with Merck.
  • asks Dr. Christian Tidona, Founder and Managing Director of the BioMed X Institute.
  • The most recently completed BioMed X project was also a Merck collaboration investigating RNA splicing patterns in cancer.

QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023

Retrieved on: 
Friday, April 14, 2023
DNA, QIAGEN, QGEN, AACR, University, Therapeutic drug monitoring, Senior, Workflow, Nucleic acid thermodynamics, NGS, Liquid biopsy, Cancer, American Association for Cancer Research, Mutation, RNA, VAF, Chemistry, Patient, Blood, Central business district, Diagnosis, Fluid mechanics, Library, Gene, NYSE, PCR, Vaccine, Medical imaging

It will be one of the central features of QIAGEN’s life-science offering at the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, from April 14 to 19, 2023.

Key Points: 
  • It will be one of the central features of QIAGEN’s life-science offering at the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, from April 14 to 19, 2023.
  • Liquid biopsy centered on cfDNA has become a vital tool in the diagnosis, outcome prognosis and treatment monitoring of cancer and other diseases.
  • “QIAGEN is dedicated to driving innovation in liquid biopsy technology to enhance cancer research and improve patient outcomes.
  • QIAGEN is looking forward to hosting AACR attendees at booth #753 in Orlando’s Orange County Convention Center.